Despite therapy, the prognosis of CNS-TB is dismal. The mortality ranges between 9.8 to 57% for TBM.

The clinical outcome depends upon the age, clinical stage, and duration of symptoms before admission of elevated CSF protein, the extent of arachnoiditis, as well as the presence of complications.